| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 核素药物(元) | 1,017,334,254.84 | 502,378,547.61 | 914,896,052.50 | 421,526,927.97 |
| 原料药相关产品(元) | 1,677,555,795.64 | 952,893,490.85 | 2,061,031,832.95 | 1,081,012,621.37 |
| 制剂产品(元) | 400,155,803.05 | 263,379,078.63 | 483,260,734.01 | 222,370,976.14 |
| 其他主营业务(元) | - | - | - | 40,151,407.47 |
| 其他产品(元) | 180,602,033.10 | 66,359,345.24 | 123,766,807.67 | 40,151,407.47 |
| 营业成本(元) | ||||
| 核素药物(元) | 277,521,946.57 | 145,873,812.59 | 259,019,444.31 | 120,457,086.07 |
| 原料药相关产品(元) | 1,239,748,447.09 | 711,270,677.87 | 1,564,775,848.00 | 850,383,480.93 |
| 制剂产品(元) | 177,607,998.66 | 83,384,725.00 | 138,538,819.40 | 61,910,216.99 |
| 其他主营业务(元) | - | - | - | 27,632,893.36 |
| 其他产品(元) | 111,079,607.06 | 48,422,514.96 | 82,041,107.97 | 27,632,893.36 |
| 毛利(元) | ||||
| 核素药物(元) | 739,812,308.27 | 356,504,735.02 | 655,876,608.19 | 301,069,841.90 |
| 原料药相关产品(元) | 437,807,348.55 | 241,622,812.98 | 496,255,984.95 | 230,629,140.44 |
| 制剂产品(元) | 222,547,804.39 | 179,994,353.63 | 344,721,914.61 | 160,460,759.15 |
| 其他主营业务(元) | - | - | - | 12,518,514.11 |
| 其他产品(元) | 69,522,426.04 | 17,936,830.28 | 41,725,699.70 | 12,518,514.11 |
| 毛利率(%) | ||||
| 核素药物(%) | 72.72 | 70.96 | 71.69 | 71.42 |
| 原料药相关产品(%) | 26.10 | 25.36 | 24.08 | 21.33 |
| 制剂产品(%) | 55.62 | 68.34 | 71.33 | 72.16 |
| 其他主营业务(%) | - | - | - | 31.18 |
| 其他产品(%) | 38.49 | 27.03 | 33.71 | 31.18 |
| 收入构成(%) | ||||
| 核素药物(%) | 31.06 | 28.14 | 25.53 | 23.35 |
| 原料药相关产品(%) | 51.21 | 53.38 | 57.52 | 59.88 |
| 制剂产品(%) | 12.22 | 14.76 | 13.49 | 12.32 |
| 其他主营业务(%) | - | - | - | 2.22 |
| 其他产品(%) | 5.51 | 3.72 | 3.45 | 2.22 |
| 毛利构成(%) | ||||
| 核素药物(%) | 50.34 | 44.78 | 42.63 | 41.98 |
| 原料药相关产品(%) | 29.79 | 30.35 | 32.25 | 32.16 |
| 制剂产品(%) | 15.14 | 22.61 | 22.41 | 22.37 |
| 其他主营业务(%) | - | - | - | 1.75 |
| 其他产品(%) | 4.73 | 2.25 | 2.71 | 1.75 |